Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...

The tagline comes with a new logo designed to be easy to read with a clean font and three arches to symbolize the waterfall at the downtown Crow River dam. It’s meant to be an uplifting logo ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Protagonist Therapeutics (PTGX – Research Report). The company’s shares closed yesterday at ...

Atsena Therapeutics (“Atsena”) is a clinical-stage gene therapy company developing best-in-class treatments for the reversal or prevention of blindness from inherited retinal diseases.

Commercial stage pharmaceutical firm Shield Therapeutics, which has a base in Gateshead, has significantly improved its revenues and strengthened its balance sheet. The company expects to report total ...

Atsena Therapeutics ("Atsena”) is a clinical-stage gene therapy company developing best-in-class treatments for the reversal or prevention of blindness from inherited retinal diseases. The company's ...

The 45th annual event kicks off on May 1, 2025, and its theme is "Game On!" The International Code Council recently announced the campaign for the 45th Annual Building Safety Month, which raises ...

Pasithea Therapeutics shares were up 67% to $3.46 in premarket trading after the company said that an external safety review committee recommended that its Phase 1 clinical trial of PAS-004 in ...

The National Interest is an award-winning online publication focusing on defense issues, national security, military affairs and hardware, foreign policy, and U.S. politics. The National Interest ...

TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the ...

Miist Therapeutics, a physics-based developer of inhaled medicines, today announced $7M in seed funding from investors including Refactor Capital, 1517 Fund, Freeflow Ventures, Entrepreneur First ...